This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
64
The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
Albany Medical Center
Albany, New York, United States
Subjects With Neurological Death or Ipsilateral Stroke
Reported incidences of death or ipsilateral stroke
Time frame: 30 days
Technical Events During the PHIL Embolization Procedure(s)
Reported incidences of technical events with PHIL device
Time frame: During the procedure
Device-related Adverse Events
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.